GlassScriptPhysician profile
Lisa Guzman
NPI 1619378148
$5,789.90
in general payments reported to CMS, 2019-2025
27 companies · $869 in 2025
The $869 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,311 · 2022: $1,375 · 2023: $1,173 · 2024: $1,062 · 2025: $869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,104.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,789.03 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $1,015.31 | 2021-2025 | Xtampza, Belbuca |
| Teva Pharmaceuticals USA, INC. | $357.63 | 2021-2023 | Austedo Xr, Austedo |
| Amgen INC. | $339.96 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $315.93 | 2022-2025 | Relistor |
| Lundbeck LLC | $291.84 | 2022-2025 | Vyepti |
| Scilex Pharmaceuticals INC. | $247.24 | 2021-2025 | |
| Virtus Pharmaceuticals LLC | $240.09 | 2023-2025 | Levorphanol Tartrate |
| Almatica Pharma LLC | $223.71 | 2021-2023 | Gralise |
| Redhill Biopharma INC. | $207.44 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $124.08 | 2021-2022 | |
| Grt US Holding, INC. | $84.66 | 2022 | |
| Novartis Pharmaceuticals Corporation | $80.43 | 2021 | |
| Pfizer INC. | $56.01 | 2025 | |
| Valinor Pharma, LLC | $47.50 | 2023-2024 | Movantik |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $45.18 | 2025 | Symbravo |
| Azurity Pharmaceuticals, INC. | $44.71 | 2024 | Horizant |
| Biodelivery Sciences International, INC. | $39.71 | 2021 | |
| Impel Pharmaceuticals INC. | $37.10 | 2022-2023 | Trudhesa |
| Ucb, INC. | $34.01 | 2021 | |
| Lilly USA, LLC | $33.89 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $31.02 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $28.74 | 2023 | Quviviq |
| Sk Life Science, INC. | $21.88 | 2021 | |
| Biogen, INC. | $21.68 | 2025 | Skyclarys |
| Seagen INC. | $17.14 | 2021 | |
| Eisai INC. | $13.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Guzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.